Disease Information
General Information of the Disease (ID: DIS00117)
Name |
Corneal ulcer
|
---|---|
ICD |
ICD-11: 9A76
|
Resistance Map |
Type(s) of Resistant Mechanism of This Disease
DISM: Drug Inactivation by Structure Modification
Drug Resistance Data Categorized by Drug
Approved Drug(s)
3 drug(s) in total
Gentamicin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Aminoglycoside N(3)-acetyltransferase (AACC2) | [1], [2] | |||
Resistant Disease | Corneal ulcers [ICD-11: 9A76.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Gentamicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli ATCC 25922 | 1322345 | ||
Pseudomonas aeruginosa ATCC 27853 | 287 | |||
Pseudomonas aeruginosa isolates | 287 | |||
Staphylococcus aureus ATCC 25923 | 1280 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Agar dilution method assay | |||
Mechanism Description | Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk). |
Netilmicin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Aminoglycoside N(3)-acetyltransferase (AACC2) | [1], [2] | |||
Resistant Disease | Corneal ulcers [ICD-11: 9A76.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Netilmicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli ATCC 25922 | 1322345 | ||
Pseudomonas aeruginosa ATCC 27853 | 287 | |||
Pseudomonas aeruginosa isolates | 287 | |||
Staphylococcus aureus ATCC 25923 | 1280 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Agar dilution method assay | |||
Mechanism Description | Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk). |
Tobramycin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Aminoglycoside N(3)-acetyltransferase (AACC2) | [1], [2] | |||
Resistant Disease | Corneal ulcers [ICD-11: 9A76.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Tobramycin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli ATCC 25922 | 1322345 | ||
Pseudomonas aeruginosa ATCC 27853 | 287 | |||
Pseudomonas aeruginosa isolates | 287 | |||
Staphylococcus aureus ATCC 25923 | 1280 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Agar dilution method assay | |||
Mechanism Description | Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk). |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.